menu
    • menu
    [{"orgOrder":0,"company":"Uniqure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2019","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Uniqure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Undisclosed"},{"orgOrder":0,"company":"Uniqure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Uniqure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Undisclosed"},{"orgOrder":0,"company":"Uniqure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Uniqure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Undisclosed"},{"orgOrder":0,"company":"Uniqure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Uniqure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Undisclosed"},{"orgOrder":0,"company":"Uniqure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Uniqure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Undisclosed"},{"orgOrder":0,"company":"Uniqure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Uniqure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Undisclosed"},{"orgOrder":0,"company":"Uniqure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Uniqure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Undisclosed"},{"orgOrder":0,"company":"Uniqure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Uniqure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Undisclosed"},{"orgOrder":0,"company":"Uniqure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Uniqure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Undisclosed"},{"orgOrder":0,"company":"Uniqure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Uniqure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Undisclosed"},{"orgOrder":0,"company":"Uniqure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Uniqure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Undisclosed"},{"orgOrder":0,"company":"Uniqure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Uniqure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Undisclosed"},{"orgOrder":0,"company":"Uniqure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Uniqure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Undisclosed"},{"orgOrder":0,"company":"Uniqure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Uniqure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Undisclosed"},{"orgOrder":0,"company":"Uniqure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Uniqure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Undisclosed"},{"orgOrder":0,"company":"Uniqure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2021","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Uniqure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Undisclosed"},{"orgOrder":0,"company":"Uniqure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Uniqure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Undisclosed"},{"orgOrder":0,"company":"Uniqure","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2025","type":"Public Offering","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Uniqure \/ Leerink Partners","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Leerink Partners"},{"orgOrder":0,"company":"Uniqure","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2025","type":"Public Offering","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Injection","sponsorNew":"Uniqure \/ Leerink Partners","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Leerink Partners"},{"orgOrder":0,"company":"Uniqure","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"AMT-130","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Injection","sponsorNew":"Uniqure \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Undisclosed"},{"orgOrder":0,"company":"Uniqure","sponsor":"Hercules Capital","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2025","type":"Financing","leadProduct":"Antimony pentoxide","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Uniqure \/ Hercules Capital","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Hercules Capital"},{"orgOrder":0,"company":"Uniqure","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"NETHERLANDS","productType":"Cell & Gene Therapy","year":"2025","type":"Public Offering","leadProduct":"Antimony pentoxide","moa":"Huntingtin (HTT)","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Uniqure","amount2":0.34999999999999998,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"Uniqure \/ Leerink Partners","highestDevelopmentStatusID":"7","companyTruncated":"Uniqure \/ Leerink Partners"}]

    Find Clinical Drug Pipeline Developments & Deals for Antimony pentoxide

    Menu

    Antimony pentoxide

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Uniqure

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Uniqure

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antimony pentoxide

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Leerink Partners

                            Deal Size : $345.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            uniQure Announces Closing of Upsized Public Offering

                            Details : uniQure intends to use the net proceeds to fund its commercialization readiness activities, the potential commercial launch of AMT-130, a one-time gene therapy for Huntington's disease.

                            Product Name : AMT-130

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            September 29, 2025

                            Lead Product(s) : Antimony pentoxide

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Leerink Partners

                            Deal Size : $345.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Uniqure

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Uniqure

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antimony pentoxide

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Hercules Capital

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Uniqure Secures $125M Non-Dilutive Funding, Refinances $50M Debt

                            Details : The financing deal will support the development of AMT-130, a gene therapy for the treatment of Huntington’s disease.

                            Product Name : AMT-130

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            September 24, 2025

                            Lead Product(s) : Antimony pentoxide

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Hercules Capital

                            Deal Size : Undisclosed

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Uniqure

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Uniqure

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antimony pentoxide

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            uniQure gets FDA Breakthrough Therapy Tag for AMT-130 in Huntington’s Disease

                            Details : AMT-130 lowers both normal and mutant huntingtin protein, currently being investigated for the treatment of Huntington’s disease.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            April 17, 2025

                            Lead Product(s) : Antimony pentoxide

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Uniqure

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Uniqure

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antimony pentoxide

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Leerink Partners

                            Deal Size : $75.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            uniQure Announces Pricing of its Public Offering

                            Details : The net proceeds will support the company to advance its AMT-130, which is being evaluated for the treatment of patients suffering from Huntington’s disease.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            January 08, 2025

                            Lead Product(s) : Antimony pentoxide

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Leerink Partners

                            Deal Size : $75.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Uniqure

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Uniqure

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antimony pentoxide

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Leerink Partners

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            uniQure Announces Proposed Public Offering

                            Details : The net proceeds will support the company to advance its AMT-130, which is being evaluated for the treatment of patients suffering from Huntington’s disease.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            January 07, 2025

                            Lead Product(s) : Antimony pentoxide

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Leerink Partners

                            Deal Size : Undisclosed

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Uniqure

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Uniqure

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antimony pentoxide

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            uniQure Alignment with FDA on Accelerated Approval for AMT-130 in Huntington’s Disease

                            Details : AMT-130 is an mHTT production inhibitor cell and gene therapy drug candidate, which is currently being evaluated for the treatment of Huntington’s disease.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            December 10, 2024

                            Lead Product(s) : Antimony pentoxide

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Uniqure

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Uniqure

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antimony pentoxide

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            uniQure Announces Positive Data for AMT-130 in Huntington Disease Trials

                            Details : AMT-130 is an mHTT production inhibitor cell and gene therapy drug candidate, which is currently being evaluated for the treatment of Huntington’s disease.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            July 09, 2024

                            Lead Product(s) : Antimony pentoxide

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Uniqure

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Uniqure

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antimony pentoxide

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            uniQure Reports Positive Interim Data for AMT-130 in Huntington Disease Trials

                            Details : AMT-130 is an mHTT production inhibitor cell and gene therapy drug candidate, which is currently being evaluated for the treatment of Huntington’s disease.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            July 09, 2024

                            Lead Product(s) : Antimony pentoxide

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Uniqure

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Uniqure

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antimony pentoxide

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            uniQure Receives FDA RMAT Designation for AMT-130 in Huntington’s Disease

                            Details : AMT-130 is an mHTT production inhibitor cell and gene therapy drug candidate, which is currently being evaluated for the treatment of Huntington’s disease.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            June 03, 2024

                            Lead Product(s) : Antimony pentoxide

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Uniqure

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Uniqure

                            Netherlands arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Antimony pentoxide

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            uniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington...

                            Details : AMT-130 is an mHTT production inhibitor cell and gene therapy drug candidate, which is currently being evaluated for the treatment of Huntington’s disease.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            December 19, 2023

                            Lead Product(s) : Antimony pentoxide

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth